Compare TNGX & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNGX | ALTI |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 409.8M |
| IPO Year | 2020 | 2021 |
| Metric | TNGX | ALTI |
|---|---|---|
| Price | $29.12 | $3.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $21.78 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 222.5K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.89 | ★ 41.11 |
| EPS | ★ N/A | N/A |
| Revenue | $62,384,000.00 | ★ $254,956,000.00 |
| Revenue This Year | N/A | $18.06 |
| Revenue Next Year | N/A | $10.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.29 | 23.21 |
| 52 Week Low | $4.60 | $2.75 |
| 52 Week High | $34.39 | $5.45 |
| Indicator | TNGX | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 51.46 |
| Support Level | $19.74 | $2.96 |
| Resistance Level | N/A | $3.93 |
| Average True Range (ATR) | 2.52 | 0.19 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 67.72 | 89.80 |
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.